Hair in the shower drain is one of the more unsettling things to notice a few months into semaglutide. It is a real side effect, listed on the label, and it is uncommon. How uncommon, and in whom, is set out below.
What the label reports
The Wegovy label pooled three 68-week weight trials [1]. Hair loss was reported by 3.3% of people on 2.4 mg and 1% on placebo. The label states that these reactions were associated with weight reduction.
The split by sex is wide. On 2.4 mg, hair loss was reported by 4% of women and 0.9% of men. On placebo it was 2% of women and no men. In the adolescent trial, 4% on 2.4 mg reported it against none on placebo.
3.3%
Reported hair loss on Wegovy 2.4 mg vs 1% on placebo (pooled weight trials)
Wegovy label
8.4%
Women reporting hair loss on 7.2 mg, vs 0.2% of men
Wegovy label
7.1%
Women reporting hair loss on tirzepatide vs 0.5% of men
Zepbound label
Does a higher dose mean more hair loss?
The newer 7.2 mg dose gives the clearest answer. In its two 72-week trials, hair loss was reported by 5.8% on 7.2 mg, 3.3% on 2.4 mg and 1.0% on placebo [1].
Among women, the figures were 8.4%, 5.4% and 1.5%. Among men they were 0.2%, 0 and 0. On 7.2 mg, one case led to stopping the drug, one to a pause, and five to a dose reduction.
The 7.2 mg dose also produced more weight loss than 2.4 mg, so the two rise together. How that dose step works is covered in semaglutide dosage.
The same pattern on tirzepatide
Hair loss is not unique to semaglutide. The Zepbound label lists it among its most common adverse reactions. In the pooled weight trials it was reported by 5%, 4% and 5% on the 5, 10 and 15 mg doses, and 1% on placebo [2].
That label also ties it to weight reduction. It was reported by 7.1% of women and 0.5% of men on tirzepatide. No one on tirzepatide stopped treatment because of it. How much weight people lost in those trials is set out in how much weight you can lose on tirzepatide.
| Label and dose | On the drug | On placebo |
|---|---|---|
| Wegovy 2.4 mg, pooled weight trials | 3.3% | 1% |
| Wegovy 2.4 mg, adolescents | 4% | 0% |
| Wegovy 7.2 mg, two 72-week trials | 5.8% | 1.0% |
| Zepbound 5, 10, 15 mg, pooled trials | 5%, 4%, 5% | 1% |
What large health-record studies found
Trials count what participants report. Health records count diagnoses. A 2026 study matched 547,993 adult users of GLP-1 drugs and controls across 67 US health systems, adjusting for age, sex, race, BMI and diabetes [3].
At 12 months, GLP-1 users had higher odds of telogen effluvium (adjusted odds ratio 1.76) and of pattern hair loss (1.64). Alopecia areata, the autoimmune form, was not linked to the drugs.
A 2026 meta-analysis pooled three cohort studies and reached an odds ratio of 1.40 for any non-scarring hair loss (95% CI 1.33 to 1.48) [4]. Its subtype figures match the 2026 study above, which it includes, so the two are not independent.
In adverse-event reporting databases, the same meta-analysis found the strongest signal for semaglutide (reporting odds ratio 2.46) and tirzepatide (1.73). Reporting databases show what gets reported, not how often it happens.
Why weight loss can shed hair
Telogen effluvium is diffuse shedding that follows a stressful event, such as childbirth, prolonged surgery, a severe fever or rapid weight loss [6]. It thins hair across the scalp rather than in patches.
A hospital dermatology department in Seoul reviewed 140 people diagnosed with telogen effluvium after weight loss [6]. Their mean loss was 15.21% of body weight, at an average of 3.54 kg a month. Older adults developed it after smaller losses, and the authors judged women especially vulnerable.
That 15% figure sits close to the average in the semaglutide weight trials. The overlap is suggestive, not proof: the clinic series was not a study of GLP-1 drugs and had no comparison group.
A 2026 dermatology commentary names rapid weight loss as the leading proposed mechanism for GLP-1 hair loss [5]. It also raises lower intake leading to shortfalls in iron, calcium and some vitamins. It states that causality has not been established.
If you notice shedding
The label evidence points to a side effect that follows weight loss and is much more common in women. What the record does not show is a proven fix.
Bring it up with the prescriber rather than changing the dose yourself. Diet quality and the pace of loss are the two things the commentary suggests reviewing [5]. The label’s other side effects are in semaglutide side effects.
For what is known about peptides marketed for hair regrowth, see peptides for hair growth. To compare prescribers, see the weight-loss peptide rankings.